Form 4: Director Marla Persky Adjusts Xeris Biopharma Holdings Stake

Director Marla Persky sold 15,500 shares of Xeris Biopharma Holdings and received a new grant of 24,193 restricted stock units and 32,996 stock options.

Summary

• Director Marla Persky sold 15,500 shares of common stock at a weighted average price of $5.8989 on June 3, 2026.
• The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on June 12, 2025.
• On June 4, 2026, the director was granted 24,193 restricted stock units (RSUs) and 32,996 stock options with an exercise price of $6.15.
• The new equity awards vest in full on the earlier of June 4, 2026, or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the sale was pre-planned and offset by a new equity grant, reflecting standard director compensation cycles.

Positives

• The director maintains a significant ongoing equity stake of 150,693 shares following the transactions.
• The sale was conducted via a pre-planned Rule 10b5-1 program, indicating the transaction was not based on non-public information.

Negatives

• The director reduced her direct holdings by 15,500 shares.

Risks

• Future share price volatility may impact the value of the newly granted stock options and RSUs.
• Vesting of new equity is contingent upon continued service to the company.

Future Outlook

The director's equity awards are set to vest on the earlier of June 4, 2026, or the next annual meeting of stockholders, contingent on continued service.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans combined with annual equity grants is standard corporate governance practice for biotech directors, signaling no change in long-term strategic outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard industry practice to mitigate legal risk for corporate insiders.
• The equity grant structure aligns with typical compensation packages for non-employee directors in the mid-cap biopharmaceutical sector.

Stakeholder Impact

• Shareholders should view this as a routine transaction given the 10b5-1 plan usage.

Next Steps

• Vesting of RSU and stock option grants on the earlier of June 4, 2026, or the next annual meeting.

Key Dates

Keywords

Xeris Biopharma, XERS, Insider Trading, Form 4, Equity Compensation, Director Transactions